AFAP1 and neoplasm: In a mouse model of metastatic breast cancer (4T1), treatment with αFAP-PE38 led to significant reduction in the recruitment of tumour infiltrating immune cells and tumour growth as monotherapy and in combination with paclitaxel (133).